Article - 07/06/2017 Industry 4.0: Pfizer opens continuous manufacturing plant in Freiburg On 23rd May 2017, Pfizer officially opened a modern continuous manufacturing plant in Freiburg, thus setting a new technological standard for tablet production. A groundbreaking ceremony to inaugurate Pfizer’s new PCMM plant was held at the same time. Pfizer is investing around 50 million euros in the Freiburg facility. https://www.gesundheitsindustrie-bw.de/en/article/news/industry-40-pfizer-opens-continuous-manufacturing-plant-in-freiburg
Article - 24/05/2017 Ralf Reski: from moss to humans Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…https://www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
Press release - 06/04/2017 Start-up in the garage – a location with prospects Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germanyhttps://www.gesundheitsindustrie-bw.de/en/article/press-release/start-up-in-the-garage-a-location-with-prospects
Article - 23/02/2017 Rentschler places formulation on biopharmaceuticals production agenda with LEUKOCARE alliance On February 2, 2017, Rentschler Biotechnologie and LEUKOCARE announced a strategic alliance in which LEUKOCARE will become the exclusive formulation developer for the Laupheim-based contract manufacturer. Rentschler will acquire a 10% stake in LEUKOCARE, a biotech company established in 2003 and headquartered in Martinsried. On behalf of BIOPRO, Walter Pytlik spoke with the two CEOs, Rentschler’s Dr. Frank Mathias and LEUKOCARE’s Michael Scholl…https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-places-formulation-on-biopharmaceuticals-production-agenda-with-leukocare-alliance
Press release - 30/01/2017 ChemCon celebrates 20th anniversary ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90…https://www.gesundheitsindustrie-bw.de/en/article/press-release/chemcon-celebrates-20th-anniversary
Dossier - 17/01/2017 Phytopharmaceuticals – fighting disease with natural substances Phytopharmaceuticals are herbal medicines whose efficacy is down to one or several plant substances or active ingredients. They have been used for treating diseases since time immemorial. This traditional knowledge is still the basis for many medicinal products made from plants or parts thereof. Herbal medicines have been produced in Baden-Württemberg for many generations. https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances
Expert interview - 14/11/2016 The great untapped potential of herbal medicines Baden-Württemberg is home to a large number of companies that produce herbal medicines, i.e. preparations made from plant extracts rather than pure compounds. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, explains how these special extracts are placed on the market and how they differ from medicines…https://www.gesundheitsindustrie-bw.de/en/article/news/the-great-untapped-potential-of-herbal-medicines
High-tech - 20/10/2016 Industry 4.0 in the medical technology and pharmaceutical industry sectors The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models. https://www.gesundheitsindustrie-bw.de/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
Article - 26/09/2016 TuCADD: Coaching for early drug candidates The University of Tübingen is optimising its drug development pipeline. The TuCADD consortium provides professional help to people who want to take potential drug candidates to clinical application. The coaching involves assistance with the entire phase I drug development phase from industry experts.https://www.gesundheitsindustrie-bw.de/en/article/news/tucadd-coaching-for-early-drug-candidates
Article - 13/09/2016 Catalent – galenics experts from Schorndorf Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.https://www.gesundheitsindustrie-bw.de/en/article/news/catalent-galenics-experts-from-schorndorf
Article - 19/07/2016 Licence to kill – the enormous potential of CAR T cells With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
Article - 27/06/2016 A nasal spray for treating neurodegenerative diseases Neuroscientists from Heidelberg have created the scientific foundations for a nasal spray that can stabilise the dendrites of nerve cells, thus reducing nerve damage and brain function losses following a stroke. Prof. Dr. Hilmar Bading and his team received the 2016 German BioRegions Innovation Prize for their invention and have set up a company called FundaMental Pharma to further accelerate the development of a marketable medicinal product.https://www.gesundheitsindustrie-bw.de/en/article/news/a-nasal-spray-for-treating-neurodegenerative-diseases
Retrospective Meet & Match Pharmaceutical Process Technology - 07/04/2016 Speed dating for Pharmaceutical Process Technology – a business flirt at Bosch The speed dating format is no longer just a popular and simple dating method for lonely hearts, but has also become a rewarding way for establishing new business contacts and connections quickly and efficiently. BIOPRO Baden-Württemberg chose speed networking, as speed dating is called in the corporate world, for its recent Meet & Match event on pharmaceutical process technology, which took place on 15th March 2016 with the support of Bosch…https://www.gesundheitsindustrie-bw.de/en/article/press-release/speed-dating-for-pharmaceutical-process-technology-a-business-flirt-at-bosch
Article - 25/01/2016 And yet another biological from Biberach Boehringer Ingelheim is an important contract manufacturer of biopharmaceuticals that also produces proprietary drugs. We spoke with Dr. Joanne van Ryn, a Canadian pharmacologist who has been doing research at Boehringer Ingelheim’s company site in Biberach for over 20 years. Her research focuses on thrombosis, haemostasis and coagulation. She is involved in the scientific monitoring of dabigatran (Pradaxa), an oral anticoagulant that, in 2008,…https://www.gesundheitsindustrie-bw.de/en/article/news/and-yet-another-biological-from-biberach
Article - 18/01/2016 New approaches in the life sciences industry: innovative strategies for courageous companies For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…https://www.gesundheitsindustrie-bw.de/en/article/news/new-avenues-in-the-life-sciences-industry-innovative-strategies-for-brave-companies
Press release - 16/11/2015 The Baden-Württemberg healthcare industry – a strong economic power (Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany. https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-baden-wuerttemberg-healthcare-industry-a-strong-economic-power
Press release - 03/11/2015 CureVac raises $110 Million in a private placement CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
Article - 30/09/2015 New synthesis method produces compound for use in tumour medicines Very few people have ever heard of the chemical compound sulphoquinovose. This natural substance is nevertheless found in a large variety of foods. Sulphoquinovose has been playing an increasing role in cancer research, which is why demand for the compound is constantly growing. With this in mind, researchers from a company called MCAT GmbH from Konstanz are working on the development a method to synthesise larger quantities of sulphoquinovose…https://www.gesundheitsindustrie-bw.de/en/article/news/new-synthesis-method-produces-compound-for-use-in-tumour-medicines
Article - 22/06/2015 Through the nose directly into the brain: Biberach researchers are working on a novel way to apply pharmaceuticals The blood-brain barrier prevents most drugs, and large biologics in particular, from entering the brain. This physiological barrier impairs the study of central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis as well as the development of drugs. However, there is a hidden side entrance to the brain, which means that there is a way to circumvent this barrier.https://www.gesundheitsindustrie-bw.de/en/article/news/through-the-nose-directly-into-the-brain-biberach-researchers-are-working-on-a-novel-way-to-apply-pharmaceuticals
The Baden-Württemberg healthcare industry Baden-Württemberg – the land of startups Setting up an independent company is an excellent way to turn innovative life sciences solutions into successful new products and services. Baden-Württemberg is highly attractive for business startups. As one of the leading German states in the fields of healthcare and biotechnology, Baden-Württemberg has an attractive and stimulating environment for those seeking to set up their own company. Baden-Württemberg has a high density of innovative…https://www.gesundheitsindustrie-bw.de/en/location/start-up
The Baden-Württemberg healthcare industry The pharmaceutical industry Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.https://www.gesundheitsindustrie-bw.de/en/location/pharma
Article - 27/10/2014 Takeda GmbH in Singen – pharmaceutical development and production under one roof From stomach protection agents to drugs for the treatment of respiratory distress in preterm infants – Singen-based Takeda GmbH plays an important role as a competence centre for drugs in liquid and semi-solid dosage form within the Japanese pharmaceutical company’s global network. Besides the production of around 68 million packages per year, the company’s production site in Singen also focuses on drug development. The company’s CMC Centre…https://www.gesundheitsindustrie-bw.de/en/article/news/takeda-gmbh-in-singen-pharmaceutical-development-and-production-under-one-roof
Article - 13/10/2014 Data mining is likely to play an increasing role in clinical development Data mining still plays a minor role in the research-based pharmaceutical industry. But this is likely to change in the future. Mathematician Hans-Jürgen Lomp predicts that exploratory data analysis will be used to a greater extent in the future. Lomp is the Global Head of Statistics in Boehringer Ingelheim Pharma GmbH & Co KG’s Department of Medical Data Service and Biostatistics in Biberach.https://www.gesundheitsindustrie-bw.de/en/article/news/data-mining-is-likely-to-play-an-increasing-role-in-clinical-development
Article - 10/06/2014 Mathematical models for predicting cellular signalling pathways The micrometre-sized cells in organisms are biological systems in which countless vital processes take place. However little is yet known about most of these cellular metabolic chains because they interact with each other in a complicated manner. The research carried out by junior professor Nicole Radde and her doctoral student and engineer Patrick Weber from the Institute for Systems Theory and Automated Control IST at the University of…https://www.gesundheitsindustrie-bw.de/en/article/news/mathematical-models-for-predicting-cellular-signalling-pathways